优化他汀类药物治疗2型糖尿病患者心血管疾病的一级预防:探索剂量、类别和强度。

Jung-Min Yu, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
{"title":"优化他汀类药物治疗2型糖尿病患者心血管疾病的一级预防:探索剂量、类别和强度。","authors":"Jung-Min Yu, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu","doi":"10.1177/14791641231214507","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the impact of statin use on primary prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in a dose-, class-, and use intensity-dependent manner.</p><p><strong>Methods: </strong>We used an inverse probability treatment-weighted Cox hazards model, with statin use status as a time-dependent variable.</p><p><strong>Results: </strong>Our results showed that statin use was associated with a significant reduction in CVD risk with an adjusted hazard ratio of 0.39. Pitavastatin was found to have the lowest CVD risk among the different classes of statins, followed by rosuvastatin, pravastatin, atorvastatin, simvastatin, fluvastatin, and lovastatin. Our analysis also revealed that a higher cumulative defined daily dose per year of statin was associated with a lower CVD risk. Additionally, a higher intensity of daily statin dose was associated with a lower CVD risk in patients with T2DM.</p><p><strong>Conclusion: </strong>This study highlights the importance of statin use in reducing the risk of CVD in patients with T2DM, and the significance of dose, class, and intensity of statin use, in particular, pitavastatin class of statins was found to be the most effective in primary prevention of CVD in T2DM.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"20 6","pages":"14791641231214507"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631324/pdf/","citationCount":"0","resultStr":"{\"title\":\"Optimizing statin therapy for primary prevention of cardiovascular disease in type 2 diabetes mellitus patients<i>:</i> Exploring dose, class, and intensity.\",\"authors\":\"Jung-Min Yu, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu\",\"doi\":\"10.1177/14791641231214507\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate the impact of statin use on primary prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in a dose-, class-, and use intensity-dependent manner.</p><p><strong>Methods: </strong>We used an inverse probability treatment-weighted Cox hazards model, with statin use status as a time-dependent variable.</p><p><strong>Results: </strong>Our results showed that statin use was associated with a significant reduction in CVD risk with an adjusted hazard ratio of 0.39. Pitavastatin was found to have the lowest CVD risk among the different classes of statins, followed by rosuvastatin, pravastatin, atorvastatin, simvastatin, fluvastatin, and lovastatin. Our analysis also revealed that a higher cumulative defined daily dose per year of statin was associated with a lower CVD risk. Additionally, a higher intensity of daily statin dose was associated with a lower CVD risk in patients with T2DM.</p><p><strong>Conclusion: </strong>This study highlights the importance of statin use in reducing the risk of CVD in patients with T2DM, and the significance of dose, class, and intensity of statin use, in particular, pitavastatin class of statins was found to be the most effective in primary prevention of CVD in T2DM.</p>\",\"PeriodicalId\":93978,\"journal\":{\"name\":\"Diabetes & vascular disease research\",\"volume\":\"20 6\",\"pages\":\"14791641231214507\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631324/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & vascular disease research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/14791641231214507\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & vascular disease research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/14791641231214507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:以剂量、类别和使用强度依赖的方式,研究他汀类药物的使用对2型糖尿病(T2DM)患者心血管疾病(CVD)一级预防的影响。方法:我们使用了一个反概率治疗加权Cox风险模型,他汀类药物的使用状态是一个时间相关变量。结果:我们的研究结果表明,他汀类药物的使用与CVD风险的显著降低相关,调整后的风险比为0.39。在不同类别的他汀类药物中,匹他伐他汀的CVD风险最低,其次是瑞舒伐他汀、普伐他汀、阿托伐他汀、辛伐他汀、氟伐他汀和洛伐他汀。我们的分析还表明,他汀类药物每年累计定义的日剂量越高,CVD风险越低。此外,他汀类药物的日剂量强度越高,T2DM患者的CVD风险越低。结论:本研究强调了他汀类药物在降低T2DM患者CVD风险方面的重要性,尤其是他汀类药物使用的剂量、类别和强度的重要性,发现匹伐他汀类他汀类药物在T2DM心血管疾病的一级预防中最有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Optimizing statin therapy for primary prevention of cardiovascular disease in type 2 diabetes mellitus patients: Exploring dose, class, and intensity.

Purpose: To investigate the impact of statin use on primary prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in a dose-, class-, and use intensity-dependent manner.

Methods: We used an inverse probability treatment-weighted Cox hazards model, with statin use status as a time-dependent variable.

Results: Our results showed that statin use was associated with a significant reduction in CVD risk with an adjusted hazard ratio of 0.39. Pitavastatin was found to have the lowest CVD risk among the different classes of statins, followed by rosuvastatin, pravastatin, atorvastatin, simvastatin, fluvastatin, and lovastatin. Our analysis also revealed that a higher cumulative defined daily dose per year of statin was associated with a lower CVD risk. Additionally, a higher intensity of daily statin dose was associated with a lower CVD risk in patients with T2DM.

Conclusion: This study highlights the importance of statin use in reducing the risk of CVD in patients with T2DM, and the significance of dose, class, and intensity of statin use, in particular, pitavastatin class of statins was found to be the most effective in primary prevention of CVD in T2DM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Five-year outcomes of patients with diabetes mellitus treated with a sirolimus-eluting or a biolimus-eluting stents with biodegradable polymer. From the SORT OUT VII trial. MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism. Prevalence and risk factors of retinal vein occlusion in individuals with diabetes: The kailuan eye study. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Association of serum syndecan-1 concentrations with albuminuria in type 2 diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1